
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc. is poised for positive growth, driven by the robust performance of its DEFINITY product, which experienced low-to-mid-teens growth in the second half of 2024 due to a temporary absence of a competitor. The company's free cash flow is projected to expand significantly, reaching an estimated $550M-$600M by 2025, up from $493M in 2024, indicating strong financial health and profitability potential. Additionally, anticipated changes to NCCN and SNMMI guidelines could increase Lantheus's targeted market for diagnostic scans from approximately 145,000 to 175,000 by the end of the decade, further enhancing its growth trajectory in precision medicine.
Bears say
Lantheus Holdings Inc. faces significant challenges leading to a negative outlook on its stock, primarily driven by decelerating growth trends following the expiration of Pylarify's TPT and projected earnings per share (EPS) dilution due to upcoming deals expected in the second half of 2025. The company has indicated that its DEFINITY growth is forecasted at low single-digit to mid-single-digit rates, which fall below the long-term expectations, complicating recovery from a tough year-on-year comparison. Furthermore, risks such as increased competition in the PSMA PET segment, potential delays in expanding new indications, and adverse effects from CMS reimbursement changes add to the uncertainties surrounding Lantheus Holdings's future financial performance.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares